Table 2.
Summary of relevant studies of Claudin 18.2-directed therapies. mAB: monoclonal antibody; AB: antibody; ADC: antibody–drug conjugate; CAR-T: chimeric antigen receptor T cells.
| Medication Name | Type | Study Phase | Trial Number |
|---|---|---|---|
| Zolbetuximab (claudiximab/IMAB362) |
mAB | III | NCT03504397, NCT03653507, NCT03505320 |
| ABO11 | mAB | I | NCT04400383 |
| MIL93 | mAB | I | NCT04671875 |
| Osemitamab, TST001 | mAB | II | NCT04495296. NCT04396821 |
| SPX-101 | mAB | I | NCT05231733 |
| IM-102 | mAB | I | NCT04735796, NCT05008445 |
| DR30303 | mAB | I | NCT05639153 |
| ZL-1211 | mAB | I | NCT05065710 |
| TORL-2 307-MAB | mAB | I | NCT05159440 |
| FL-301 (NBL-015) | mAB | I | NCT05153096 |
| AMG-910 | Bispecific AB | I | NCT04260191 |
| Q-1802 | Bispecific AB | I | NCT04856150 |
| ASP2138 | Bispecific AB | I | NCT05365581 |
| QLS31905 | Bispecific AB | I | NCT05278832 |
| TPX-4589 | ADC | I | NCT05001516, NCT05934331 |
| EO-3021/SYSA-1801 | ADC | I | NCT 05009966 |
| CMG901 | ADC | I | NCT04805307 |
| RC118 | ADC | I | NCT04914117, NCT05205850 |
| SOT102 | ADC | I/II | NCT05525286 |
| ATG-022 | ADC | I | NCT05718895 |
| CAR-CLD18 T | CAR-T | - | NCT03159819 |